The subject technology relates generally to apparatuses and methods for blood vessel occlusion and vascular stenting.
Veins can become incompetent through the weakening of blood vessel walls or damage to or weakening of valves within the vein. Most frequently, veins carrying oxygen-depleted blood up the legs provide the most apparent visual evidence of the vessel wall or valve weakening, demonstrating that a portion of the veins have become incompetent. When the blood vessel walls weekend or the valves no longer serve their function of reducing or preventing backflow of blood, the vain can become enlarged, weak, and twisted. This condition is referred to as a varicose vein.
While the causes of varicose veins are varied and common, varicose veins can be treated using a variety of procedures.
Treatment of varicose veins and other blood vessel problems can be achieved through some embodiments disclosed herein. Some embodiments herein relate to vessel occlusion by delivery of radially expandable implant frames that achieve immediate total occlusion of blood flow. Frame configurations, expected delivered and expanded dimensions, and a description of target anatomy of some embodiments is provided.
Aspects of implants and delivery devices that can be utilized in combination with the implants, systems, methods, and features disclosed herein are disclosed in: U.S. patent application Ser. No. 12/826,593, filed on Jun. 29, 2010; U.S. patent application Ser. No. 13/367,338, filed on Feb. 6, 2012; U.S. Patent Pub. No. US20120095489, published on Apr. 19, 2012; U.S. patent application Ser. No. 13/828,974, filed on Mar. 14, 2013, U.S. patent application Ser. No. 14/044,794, filed on Oct. 2, 2013; U.S. patent application Ser. No. 61/835,406, filed on Jun. 14, 2013; U.S. Patent App. No. 61/904,376, filed on Nov. 14, 2013; U.S. Patent App. No. 61/904,379, filed on Nov. 14, 2013; U.S. Patent App. No. 61/835,461, filed on Jun. 14, 2013; U.S. Patent App. No. 61/900,321, filed on Nov. 5, 2013; and U.S. patent application Ser. No. 14/101,171, filed on Dec. 9, 2013, the entireties of which are incorporated herein by reference.
Additionally, some embodiments provided herein relate to implantation in small blood vessels (veins or arteries), such as from about 3 mm to about 20 mm, from about 5 mm to about 15 mm, or from about 7 mm to about 11 mm. The target delivery profile can be from about 2 Fr to about 6 Fr, and in some embodiments, from about 3 Fr to about 5 Fr.
Further embodiments can provide vascular stenting for vessels that are from about 3 mm to about 16 mm, from about 5 mm to about 13 mm, and in some embodiments, from about 7 mm to about 11 mm. The target delivery profile can be from about 2 Fr to about 8 Fr, about 3 Fr to about 7 Fr, from about 4 Fr to about 6 Fr, or in some embodiments, about 5 Fr. Additionally, expansion of the implant can provide sufficient radial force against the inside wall of a vein. Some embodiments can comprise features or means configured to minimize backflow of blood or minimize venous insufficiency. For example, treatment applications for embodiments of the device can include ilio-femoral venous obstruction and chronic iliac venous outflow obstruction as a result of venous disease.
Further, some embodiments provided herein can be used to provide temporary or permanent occlusion of a vessel during and/or after treatment of a tumor by intravascular injection of fluids, chemotherapy drugs, liquid embolic agents, and/or other therapeutic agents delivered into the feeding vessels and/or into the tumor.
Some embodiments of the implants provided herein can be manufactured via several methods including shape-setting of drawn wire, chemical etching of a NiTi sheet of material, laser cutting of a tubular member, such as a material sheet or tubing, and/or electrical discharge machining (EDM) of a tubular member, such as a material sheet or tubing.
The implants disclosed herein can comprise flexible and/or shape memory materials such that they may be distorted from an expanded shape to a smaller diameter or straight shape to allow for delivery to a target location by way of a minimally invasive catheter-based approach.
In accordance with some embodiments, the implant can comprise a frame and a cover material. The cover material can comprise ePTFE tubing, film, and/or suture for attachment purposes. Additionally, the cover material may be fibrous, mesh-like, or impermeable in density.
The implant frame and/or implant cover can comprise a collagen coating or collagen treatment to improve anchoring of the implant in the target vessel. The collagen can be configured to promote cell adhesion to implant materials, thereby facilitating improved support for the implant and vessel structure while acting as an anti-migration feature for the implant.
The implant frame can comprise a straight or constant diameter, a tapering diameter, or sections of variable diameter extending over its length, which can facilitate anchoring within a vessel and optimal deployment function.
Some embodiments of the systems and devices disclosed herein address the unmet need for a device that can provide a fast, precise and reliable way to close a bodily lumen. The endoluminal occlusion system can include two major subsystems: a guide sheath assembly and an implant carrier assembly. The implant carrier assembly can include an implant device and a handle assembly. Embodiments of the present disclosure can also comprise various features disclosed in U.S. Pat. No. 8,328,840, issued on Dec. 11, 2012, the entirety of which is incorporated herein by reference.
Additional features and advantages of the subject technology will be set forth in the description below, and in part will be apparent from the description, or may be learned by practice of the subject technology. The advantages of the subject technology will be realized and attained by the structure particularly pointed out in the written description and embodiments hereof as well as the appended drawings.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the subject technology.
The accompanying drawings, which are included to provide further understanding of the subject technology and are incorporated in and constitute a part of this specification, illustrate aspects of the subject technology and together with the description serve to explain the principles of the subject technology.
In the following detailed description, numerous specific details are set forth to provide a full understanding of the subject technology. It should be understood that the subject technology may be practiced without some of these specific details. In other instances, well-known structures and techniques have not been shown in detail so as not to obscure the subject technology.
While the present description sets forth specific details of various embodiments, it will be appreciated that the description is illustrative only and should not be construed in any way as limiting. It is contemplated that although particular embodiments of the present inventions may be disclosed or shown in particular contexts, such embodiments can be used in a variety of endoluminal applications. Various applications of such embodiments and modifications thereto, which may occur to those who are skilled in the art, are also encompassed by the general concepts described herein.
The present disclosure provides various embodiments of an expandable device, such as a stent, and a catheter for supporting and delivering the stent, as well as methods of using the devices and catheters.
According to some embodiments, an occlusion system can quickly and reliably close vessels (veins or arteries) such as incompetent venous perforators and arterial venous fistulae. Some embodiments can be performed using minimally invasive techniques that allow a clinician to provide rapid and effective treatment for a variety of vascular conditions.
For example, some methods can be provided in which a clinician penetrates percutaneously to a target vessel using a delivery system. The delivery system can comprise a catheter configured to access the target vessel. In some embodiments, the catheter can be a short needle. The percutaneous access can be made at a point closest to the target vessel, such as a perforator-hemorrhage site. Further, in some embodiments, an ultrasound device (such as a handheld ultrasound device) can be used as a visualization tool to facilitate placement of the needle within the target vessel.
Further, some methods can be provided in which a clinician percutaneously accesses a target vessel using a catheter. The catheter can be guided to the proper location in the target vessel using image-guided endovascular placement. The catheter can be used to deliver a device that closes or occludes the target vessel.
According to some embodiments, devices, catheters, systems, and methods disclosed herein can be used for percutaneous, peripheral occlusion of the arterial and venous vasculature. For example, some embodiments can be used to treat pelvic venous incompetence, varicocele, gonadal vein for pelvic varices in females with chronic pelvic pain, stop blood loss from a damaged blood vessel due to a traumatic arterial injury, stop hemorrhage caused by a neoplasia, and close an abnormal blood vessel or blood vessels supplying a vascular anomaly such as arteriovenous malformations or arteriovenous fistulas, and other conditions.
According to some embodiments, devices, catheters, systems, and methods disclosed herein can also be used for percutaneous, peripheral stenting of the arterial and venous vasculature.
Some embodiments disclosed herein can be used to treat various insufficiencies in the vasculature. For example, some embodiments can be used to treat venous insufficiencies in a variety of vessels of the venous anatomy, such as between deep veins and perforator veins, including the common femoral, the deep femoral, the external iliac, the femoral, the popliteal, the anterior and/or posterior tibial, and the peroneal veins.
The venous system comprises superficial veins, deep veins, and perforator veins that fluidly interconnect the superficial veins with the deep veins. Deep veins are located within the muscle fascia and allow a high volume and pressure of blood to pass therethrough, accounting for approximately 90-95% of venous blood return to the heart. Perforator veins connect the superficial and deep venous networks in the extremities, draining blood to the deep veins as part of the process of returning oxygen-depleted blood to the heart.
Perforator veins have one-way valves designed to prevent backflow of blood down towards the superficial veins. When those valves no longer function properly and reflux occurs, the buildup of blood and pressure can cause not only the superficial veins but the perforators themselves to become incompetent. Perforator veins in the lower leg and ankle are particularly vulnerable to distention and incompetence, and the resultant circulatory problems create an increased likelihood of edema, skin discoloration, dermatitis and skin ulcers in the immediate area. Perforator vessels can include: thigh perforators (perforators of the femoral canal and inguinal perforators); knee perforators (medial, lateral, supra-, and infrapatellar and popliteal fossa perforators); leg perforators (medial perforators (paratibial and lower, middle and upper posterior tibial), lateral perforators, anterior perforators, posterior perforators (gastrocnemius, intergemellar, and para-Achillean)); ankle perforators (medial, lateral, and anterior perforators); and foot perforators (medial, lateral, dorsal, and plantar perforators).
Superficial veins serve to drain blood from the skin. Blood travels from the superficial veins through the perforator veins to the deep veins. Superficial veins are located near the surface of the skin, outside of the muscle fascia, and they account for approximately 5-10% of venous blood return to the heart. There are two primary superficial veins: the small saphenous vein (SSV) and the great saphenous vein (GSV).
In accordance with some embodiments, a medical implant can be provided that can be used in a variety of clinical applications, such as vessel occlusion, stenting, or other functions within a body vessel. The medical implant can comprise a frame and one or more secondary components.
The frame can comprise one, two, or more resilient members, such as wires, rings, coils, and other components, which can be drawn out into a delivery configuration in which the frame is in a collapsed configuration and thereafter expands to an expanded state when released from a delivery device, such as a catheter.
Referring now to the figures,
In some embodiments, the device 100 can comprise two or more support members that are coupled to at least one link member. Further, the frame member 202 can be self-expandable. In some embodiments, the frame member 202 can also be expandable under the application of force (such as by a balloon), or by electricity or heat (such as by reaching a transition temperature less than the temperature of the human body).
The frame member 202 can comprise a proximal support member 210, a distal support member 212, and at least one link member 214 extending between the proximal and distal members 210, 212. The link member 214 can be coupled to the proximal member 210 and the distal member 214 at respective first and second ends 220, 222 of the link member 214.
As shown in
In some embodiments, the frame member can also comprise a variety of structures, including a coil that follows a helical path. Various embodiments that can be used in accordance with the inventions disclosed herein are disclosed in Applicant's co-pending patent applications: U.S. patent application Ser. No. 12/826,593, filed on Jun. 29, 2010; U.S. patent application Ser. No. 13/367,338, filed on Feb. 6, 2012; U.S. Patent Pub. No. US20120095489, published on Apr. 19, 2012; U.S. patent application Ser. No. 13/828,974, filed on Mar. 14, 2013, U.S. patent application Ser. No. 14/044,794, filed on Oct. 2, 2013; U.S. Patent App. No. 61/835,406, filed on Jun. 14, 2013; U.S. Patent App. No. 61/904,376, filed on Nov. 14, 2013; U.S. Patent App. No. 61/904,379, filed on Nov. 14, 2013; U.S. Patent App. No. 61/835,461, filed on Jun. 14, 2013; U.S. Patent App. No. 61/900,321, filed on Nov. 5, 2013; and U.S. patent application Ser. No. 14/101,171, filed on Dec. 9, 2013, the entireties of which are incorporated herein by reference.
The occlusive member 204 can be coupled to the frame member 202 can be configured to facilitate at least partial occlusion of the target vessel into which the device 100 is placed. In some embodiments, the occlusive member 204 can comprise an ePTFE membrane or cap that extends around and/or is coupled to the frame member 202.
The occlusive member 204 can comprise a proximal end portion 230 and a distal end portion 232. At least one of the proximal end portion 230 and the distal end portion 232 can be coupled to the frame member 202. For example, in some embodiments, the occlusive member 204 can be coupled to the frame member 202 and/or be configured as illustrated in applicant's co-pending U.S. patent application Ser. No. 14/101,171, filed Dec. 9, 2013 (084988-0046); Ser. No. 14/044,794, filed on Oct. 2, 2013 (084988-0039); and Ser. No. 13/828,974, filed on Mar. 14, 2013 (084988-0030), the entirety of which is incorporated herein by reference.
The frame member 202 is illustrated in the expanded state 240 in
According to some embodiments, the collapsed state of the device can enable the device to be delivered to a target vessel in a low profile size. Subsequently, the device can expand, such as by self-expansion or otherwise, in order to be released and anchored in the target vessel.
Some embodiments can be configured such that proximal and/or distal end portions of the implant expand to a diameter much greater than a diameter of a central portion of the implant such that expansion of the implant reduces or eliminates one or more degrees of motion of the device relative to surrounding vasculature.
For example, as illustrated in
In some embodiments, the device can be configured to be resiliently biased toward an expanded configuration. Thus, the device can be loaded onto a catheter or other delivery mechanism in a delivery or collapsed configuration and, when released, be expanded or spring back to the expanded configuration in the target vessel.
Further, in accordance with some embodiments, the one or more link members can be configured to exert an active foreshortening force between the proximal and distal end portions when the device is in the expanded configuration.
The one or more link members can be shaped in way that upon release from the delivery mechanism, each link member tends to bring opposing support members together as close as possible by springing back or rebounding into a predetermined V or parabola shape. Thus, in the collapsed configuration, each link member can be elongated or stretched along the longitudinal axis in a state of tension. When the device is released from constraint and allowed to expand towards the expanded configuration, each link member can return to a predetermined shape, causing the length of the device to become foreshortened.
For example, in the embodiment illustrated in
Some embodiments can foreshorten by between about 10% and about 90% of the length of the device 100 in the collapsed state 242. The collapsed length of the device 100 can be measured either using the furthest points of opposing ends or using the points at which the link member(s) interconnects with the proximal and/or distal members.
The length of each link member as set and deployed, which can determine the distance between adjacent rings in the expanded configuration (manifesting the vessel closure position) can be between about 3 mm and about 20 mm, between about 4 mm and about 15 mm, between about 6 mm and about 12 mm, between about 8 mm and about 10 mm, or between about 4 mm and about 10 mm. Accordingly, in the collapsed configuration, the length of each link member can be correspondingly increased based on the geometry of the link member in the expanded configuration versus in the collapsed configuration.
In some embodiments, in the expanded configuration, a length of the frame member 202 may be between about 7 mm and about 15 mm, between about 8 mm and about 12 mm, or between about 9 mm and about 10 mm.
As illustrated in embodiments disclosed herein, the device can comprise two or more link members. The link members can, when seen in side view, have a generally V or parabolic shape. The link members can extend helically about the periphery, outer surface, or circumference of the device. In some embodiments, a path of a link member can reverse direction, such as a helical path reversing pitch, as the link member extends between support members.
For example, as illustrated in
In accordance with some embodiments, in order to achieve the expanded state 240, the frame member 202 can be configured such that interactions between its component parts and material properties of the component parts tend to create a preferred or default position to which the frame member 202 resiliently expands. Further, in some embodiments, the frame member 202 can be deflectable and deformable from the collapsed configuration to the expanded configuration in order to deliver the device to the target vessel.
In some embodiments, a first plane passing through the proximal member 210 and a second plane passing through the distal member 212 can each undergo a rotational or angular movement relative to the longitudinal axis when the frame member 202 moves from the collapsed configuration 242 to the expanded configuration 240. This movement is shown generally in
For example, in the collapsed configuration 242, the frame member 202 can be configured such that at least one of the proximal member 210 or the distal member 212 extends substantially parallel or oblique relative to a longitudinal axis of the device 100. When the proximal member 210 and/or the distal member 212 move(s) from the collapsed configuration 242 to the expanded configuration 240, the first and/or second plane(s) can move angularly or rotate relative to the longitudinal axis. For example, as illustrated in
The first and/or second planes can be arbitrary planes that correspond to the respective proximal and distal members. The location or orientation of the planes relative to the members can each be determined based on shape, size, or other characteristics of the members. For example, the planes can each pass through a maximal amount or mass of the respective members. Further, the planes can also be defined by one or more surface features of the members. For example, if the members comprise planar annuli, a top or bottom surface of each annulus can serve to define the extent of the plane.
The degree of rotation or angular movement of the first and/or second planes can be between about 10° and about 170°, including any of the angular ranges or angles therebetween, which will not be listed here for brevity.
For example, plane(s) passing through the proximal or distal member can be oriented within about 45° or less of the longitudinal axis when in the collapsed configuration 242. For example, as illustrated in
The degree of rotation or angular movement, as well as the degree of foreshortening, can be measured based on the movement of the proximal and/or distal members outside of the body or when placed in situ.
In accordance with some embodiments, the support members (e.g., the proximal and distal members 210, 212) can be configured to pop up post-deployment in order to provide reliable closure of the target vessel or hole. Further, because a target vessel may be fairly short (such as in the case of a venous perforator vessel), the device can be configured to draw opposing ends thereof into a foreshortened configuration. The support members can comprise rings that can be made as solid shapes or as open spirals.
Each support member can have a maximum cross-sectional dimension of between about 6 mm and about 20 mm. In some embodiments, the maximum cross-sectional dimension can be between about 8 mm and about 16 mm, between about 10 mm and about 15 mm, between about 12 mm and about 14 mm, between about 8 mm and about 12 mm, or between about 10 mm in 15 mm. In some embodiments, each support member can be configured as a circular or annular shape. Accordingly, a support member can define a diameter in any of the above-noted ranges. Further, the support member can be deflectable and the maximum cross-sectional dimension can represent the maximum cross-sectional dimension of the support member in the expanded configuration. Therefore, the support member can be deflected such that a deflected cross-sectional dimension in the collapsed configuration is greater than the maximum cross-sectional dimension in the expanded configuration.
In the expanded configuration, a cross-sectional dimension of the proximal and distal end portions of the device (due to the cross-sectional dimension of the corresponding support member) can be greater than a cross-sectional dimension of a central portion of the device. For example, a cross-sectional dimension of the central portion 114 can be between about 2 mm and about 10 mm. Thus, when in the expanded configuration, the central portion 114 can have a cross-sectional dimension that is less than the cross-sectional dimensions of the proximal and/or distal end portions of the device. Such an embodiment as illustrated in
Delivery of the implant device can be performed using a delivery system that maintains the implant device in a constrained or collapsed configuration while being advanced to the target area. The delivery system can carry the implant device in the collapsed configuration until reaching the target area and thereafter be actuated to release the implant device at the target area. The actuation of the delivery system can be performed in accordance with some of the embodiments disclosed herein. Further, in accordance with some embodiments, the delivery system can comprise a catheter or a needle delivery member.
As illustrated in
The actuation and function of the delivery system can incorporate features disclosed in Applicant's co-pending patent application Ser. No. 14/101,171, filed Dec. 9, 2013 (084988-0046); Ser. No. 14/044,794, filed on Oct. 2, 2013 (084988-0039); and Ser. No. 13/828,974, filed on Mar. 14, 2013 (084988-0030), the entireties of each of which are incorporated herein by reference.
According to some embodiments, the device can be engaged, supported, and/or housed along a distal portion of the system. Some embodiments can advantageously provide a needle delivery member that has a small cross-sectional profile.
For example, the needle or needle delivery member can comprise a needle profile that defines an outer diameter from about 3 Fr, 4 Fr, 5 Fr, 6 Fr, 7 Fr, 8 Fr, or 9 Fr, as noted in Table 1 below and discussed further herein.
As illustrated in
In use, the delivery system 400 can be advanced to a target vessel, such as an incompetent perforator vessel that is to be closed. The needle component 402 can be advanced into the tissue of the patient and delivered as illustrated in
As shown in
Once the distal end 470 of the catheter 404 is in the proper position within the deep vein 464, the implant distal portion 412 can be released from engagement with the catheter 404. In order to release the implant device 410, the distal end portion 412 can be released as shown in
In case of occlusion of AVF, the delivery system can be configured similarly to that described above with respect to
Referring now to
The link member 620 can be configured to rebound or assume a U- or V-shaped configuration when in the expanded configuration 602. The device can be coupled to a catheter 650 and released there from when delivered to the target vessel, as illustrated in
In accordance with some embodiments, in order to facilitate engagement with the catheter 650, the device 600 can comprise proximal and distal apertures 660, 662 configured to be engaged with an actuation wire 652 at respective first and second slots 670, 672 of the catheter 650. The implant device 600 can be coupled to the catheter as illustrated in
In accordance with yet another embodiment,
As shown in
According to various embodiments of the subject technology, the support frame may comprise at least one of stainless steel, nickel titanium (NiTi), cobalt chromium (CoCr), titanium, a polymer, a polyester based material, a tyrosine based polycarbonate, a polyethylene based material, Teflon (e.g., including expanded Teflon), and other suitable materials known to those of ordinary skill in the art. In some embodiments, the support frame may comprise at least one of polyethylene, polyglicolide, polylactide, c-caprolactone, polycarbonate, hydroxyalkanote, para dioxinine, polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), PLA, PGA, PLLA, PDLLA, PDO, PCL, and other suitable materials known to those of ordinary skill in the art. In some embodiments, the support frame and/or occlusion membrane may comprise a bioabsorbable material, beneficially allowing for their controlled degradation. In some embodiments, the support frame and/or occlusion membrane may be formed of bioabsorbable material to have a controlled degradation anywhere between about 3 months to about 3 years depending on the desired application of support frame. In some embodiments, the controlled degradation may be less than about 3 months or greater than about 3 years. For example, hydrolysis of ester linkages or effects of enzymatic degradation may be utilized for the controlled degradation.
According to various embodiments of the subject technology, occlusion membrane may be used to occlude, partially or completely, luminal structure in which an implant is deployed. In some embodiments as used herein, occlusion may refer to either partial or complete occlusion. Some embodiments can be deployed in vessels having dimensions of between about 3 mm to about 20 mm. This exceptional and advantageous ability of embodiments of the medical implants disclosed herein to provide stenting in such small vessels is made possible, for example, due to the minimal delivery profile can be achieved using such embodiments. The target delivery profile can be about 8 Fr or smaller. Further, some embodiments can optionally comprise a fibrous membrane component, in various clinical applications, as discussed above. According to some embodiments, implants disclosed herein having a fibrous membrane feature can have an expanded diameter of between about 3 mm to about 22 mm.
According to various aspects of the subject technology, implants disclosed herein may be used for various applications for reducing or stopping flow through a luminal structure in a patient. Implants of the subject technology may be used for rapid, well-controlled, and reliable occlusion of luminal structures. For example, the luminal structure may comprise at least one of a blood vessel, a body organ, a lung, an airway, a Fallopian tube, a cervical canal, a vagina, a cervix, a vas deferens, a bronchus, a ureter, a colon, a rectum, an anus, a bio duct, a pancreatic duct, or other suitable tubular structures known to those of ordinary skill in the art. Some embodiments can be used to close a ductus arteriosis from a patent ductus arteriosis. In some embodiments, implants of the present disclosure may be used for temporary occlusion in cases of lung disease, or for temporary occlusion of female reproductive organs for contraceptive purposes. In some embodiments, implants of the present disclosure may be removed, or flow may be restored through the luminal structure to restore original organ functions.
In some embodiments, implants of the present disclosure may be used for various endoluminal occlusion procedures, including procedures for the lungs (e.g., selective endobronchial occlusion for lung reduction, occlusion of bronchopleural or bronchocutaneous fistulas, endovascular occlusion of pulmonary AVMs and fistulas or aortopulmonary anastomoses) and procedures for reproductive organs (e.g., endoluminal occlusion of vas deferens or Fallopian tubes for minimally-invasive contraceptive intervention, endovascular occlusion of varicocele in males and low abdominal gonadal veins for reducing or completely eliminating chronic pelvic pain syndrome in females). In some embodiments, implants of the present disclosure may be used for reducing or stopping blood loss from a damaged blood vessel, closing an abnormal blood vessel or a blood vessel supplying a vascular anomaly, or interrupting blood supply to an organ or part of an organ for permanent devascularization (e.g., closure of splenic artery in spleen laceration, devascularization of tissues involved by neoplastic process, either pre-operatively or as a palliative measure). In some embodiments, implants of the present disclosure may be used for various endovascular (e.g., neural and peripheral) procedures including procedures for giant cerebral and skull base aneurysms (ruptured and non-ruptured), head and neck arteriovenous fistulas, dissecting intracranial and extracranial vessels, traumatic and non-traumatic vessel injury or rupture (e.g., pelvic hemorrhages in trauma patients, carotid blow-out in patients with head and neck cancers, hemorrhage induced by a neoplasia, etc.), and devascularization prior to (or as an alternative to) surgical resection of various organs or tumors.
In certain embodiments, implants of the present disclosure may be used for various organs, including for example, the spleen (e.g., endovascular occlusion as a preoperative intervention or as an alternative to surgical resection with indications including traumatic hemorrhage, hypersplenism, bleeding secondary to portal hypertension or splenic vein thrombosis, and various disorders such as thalassemia major, thrombocytopenia, idiopathic thrombocytopenic purpura, Gaucher disease, and Hodgkin disease), the liver (e.g., occlusion of portal veins collaterals as adjunct to a transjugular intrahepatic portosystemic shunt (TIPS), occlusion of the TIPS itself in cases of encephalopathy, occlusion of intrahepatic arterioportal fistulas), the kidney (e.g., endoluminal ureteral occlusion for intractable lower urinary tract fistula with urine leakage, or for the treatment of uretero-arterial fistulae, endovascular occlusion as an alternative to surgical resection for end-stage renal disease or renovascular hypertension requiring unilateral or bilateral nephrectomy and renal transplant with native kidneys in situ), and the heart (e.g., occlusion of coronary arteriovenous fistulas, transarterial embolization of Blalock-Taussig shunts). The application of implants of the present disclosure is not limited to applications for human patients, but may also include veterinary applications.
According to some embodiments, covers (including patches) disclosed herein and in the above-noted patent applications, including but not limited to the cover 132, can be attached to a respective implant. Covers disclosed herein may be attached to one or both ends or an implant and/or a middle region of an implant.
According to various embodiments of the subject technology, covers may be used to occlude, partially or completely, luminal structure in which a respective implant is deployed. In some embodiments as used herein, occlusion may refer to either partial or complete occlusion. In some embodiments, covers include at least one of a polyurethane, a polyanhidrate, PTFE, ePTFE, silicone, and other suitable materials known to those of ordinary skill in the art. In some embodiments, covers may be elastic. In some embodiments, covers may be permeable or non-permeable.
In some embodiments, an average thickness of a cover is between about 0.0005 inches and about 0.006 inches. In some aspects, the average thickness of a cover may be less than about 0.0005 inches or greater than about 0.006 inches. In certain embodiments, an average thickness of a distal portion of a cover is greater than an average thickness of a proximal portion of a cover. Such a configuration may ensure that more flow may be reduced at the distal portion of a cover. In some embodiments, the average thickness of the distal portion of a cover is between about 0.002 inches and about 0.012 inches. In some embodiments, the average thickness of the distal portion of a cover may be less than about 0.002 inches or greater than about 0.012 inches. In some embodiments, the average thickness of the proximal portion of a cover is between about 0.0005 inches and about 0.006 inches. In some embodiments, the average thickness of the proximal portion of a cover may be less than about 0.0005 inches or greater than about 0.006 inches.
Illustration of Subject Technology as Clauses
The subject technology is illustrated, for example, according to various aspects described below. Various examples of aspects of the subject technology are described as numbered clauses (1, 2, 3, etc.) for convenience. These are provided as examples and do not limit the subject technology. It is noted that any of the dependent clauses may be combined in any combination, and placed into a respective independent clause, e.g., clause 1 or clause 55. The other clauses can be presented in a similar manner.
Clause 1. An expandable device for delivery to a target location in a body vessel, comprising: a frame comprising proximal and distal members and a link member having a first end coupled to the proximal member and a second end coupled to the distal member, the proximal and distal members being at opposite ends of a longitudinal axis; wherein the frame is expandable from (1) a collapsed configuration in which (i) a first plane passes through the proximal member and a second plane passes through the distal member, and (ii) the link member extends substantially parallel relative to the longitudinal axis, to (2) an expanded configuration, in moving to which (a) the first and second planes each move angularly, relative to the longitudinal axis, from the collapsed configuration by between about 10 degrees and about 170 degrees, and (b) the link member foreshortens along the longitudinal axis to bias the proximal member toward the distal member; and a cover member coupled to the frame.
Clause 2. The device of Clause 1, wherein at least one of the proximal or distal members comprises an annular shape.
Clause 3. The device of Clause 2, wherein the proximal and distal members each comprise an annular shape.
Clause 4. The device of any of Clauses 2-3, wherein, in the collapsed configuration, the annular shape is positioned in an oblong, deflected state.
Clause 5. The device of any of Clauses 2-4, wherein, in the expanded configuration, the annular shape is positioned in a substantially circular state.
Clause 6. The device of any of Clauses 2-5, wherein the annular shape has an expanded diameter of between about 5 mm and about 15 mm.
Clause 7. The device of Clause 6, wherein the annular shape has an expanded diameter of between about 7 mm and about 13 mm.
Clause 8. The device of Clause 7, wherein the annular shape has an expanded diameter of between about 8 mm and about 12 mm.
Clause 9. The device of any of Clauses 1-8, further comprising a second link member having a first end coupled to the proximal member and a second end coupled to the distal member.
Clause 10. The device of Clause 9, wherein the first and second link members extend in opposite directions about a periphery of the device.
Clause 11. The device of any of Clauses 9-10, wherein the first and second link members extend in opposite directions about a circumference of the device.
Clause 12. The device of any of Clauses 1-11, wherein, in the collapsed configuration, the first and second end sections of the proximal and distal members are positioned substantially parallel relative to the longitudinal axis.
Clause 13. The device of any of Clauses 1-12, wherein the proximal and distal members each comprise a midsection and opposing first and second end sections, and wherein the link member first end is coupled to the proximal member midsection and the link member second end is coupled to the distal member midsection.
Clause 14. The device of any of Clauses 1-13, wherein the proximal and distal members each comprise opposing first and second end sections separated by a midsection, the longitudinal axis passing through the midsection, and wherein, in the collapsed configuration, the first and second end sections of the proximal and distal members are spaced at a first distance from the longitudinal axis, and wherein, in the expanded configuration, the first and second sections of the proximal and distal members are spaced at a second distance from the longitudinal axis, the first distance being less than the second distance.
Clause 15. The device of Clause 14, wherein the link member first end is coupled to the proximal member midsection and the link member second end is coupled to the distal member midsection.
Clause 16. The device of any of Clauses 1-15, wherein, in the expanded configuration, at least one dimension of the proximal member expands within the first plane and at least one dimension of the distal member expands within the second plane.
Clause 17. The device of Clause 16, wherein the proximal and distal members comprise an annular shape, wherein, in the collapsed configuration, the proximal and distal members are positioned in a substantially oblong shape, and wherein, in the expanded configuration, the proximal and distal members are positioned in a substantially circular shape.
Clause 18. The device of any of Clauses 1-17, wherein, in the collapsed configuration, the first and second planes each are oriented at angles of between about 10° and about 50° relative to the longitudinal axis.
Clause 19. The device of any of Clauses 1-18, wherein, in the collapsed configuration, the first and second planes each are oriented at angles of between about 20° and about 40° relative to the longitudinal axis.
Clause 20. The device of any of Clauses 1-19, wherein, in the collapsed configuration, the first and second planes each are oriented at angles of between about 25° and about 35° relative to the longitudinal axis.
Clause 21. The device of any of Clauses 1-20, wherein, in the collapsed configuration, the first and second planes each are oriented at an angle of about 30° relative to the longitudinal axis.
Clause 22. The device of any of Clauses 1-21, wherein, in the expanded configuration, the first and second planes each are oriented at angles of between about 70° and about 110° relative to the longitudinal axis.
Clause 23. The device of any of Clauses 1-22, wherein, in the expanded configuration, the first and second planes each are oriented at angles of between about 80° and about 100° relative to the longitudinal axis.
Clause 24. The device of any of Clauses 1-23, wherein, in the expanded configuration, the first and second planes each are oriented at angles of between about 85° and about 95° relative to the longitudinal axis.
Clause 25. The device of any of Clauses 1-24, wherein, in the expanded configuration, the first and second planes each are oriented at an angle of about 90° relative to the longitudinal axis.
Clause 26. The device of any of Clauses 1-25, wherein, in the expanded configuration, the link member foreshortens by moving from a substantially linear configuration to an arcuate configuration.
Clause 27. The device of any of Clauses 1-26, wherein the link member is substantially helical shaped.
Clause 28. The device of any of Clauses 1-27, wherein the link member is substantially U-shaped.
Clause 29. The device of any of Clauses 1-28, wherein the device foreshortens by over 20% when expanding from the collapsed configuration to the expanded configuration.
Clause 30. The device of any of Clauses 1-29, wherein the device foreshortens by over 30% when expanding from the collapsed configuration to the expanded configuration.
Clause 31. The device of any of Clauses 1-30, wherein the device foreshortens by over 40% when expanding from the collapsed configuration to the expanded configuration.
Clause 32. The device of any of Clauses 1-31, wherein the device foreshortens by over 50% when expanding from the collapsed configuration to the expanded configuration.
Clause 33. The device of any of Clauses 1-32, wherein the device foreshortens by over 60% when expanding from the collapsed configuration to the expanded configuration.
Clause 34. The device of any of Clauses 1-33, wherein the device foreshortens by over 70% when expanding from the collapsed configuration to the expanded configuration.
Clause 35. The device of any of Clauses 1-34, wherein the device foreshortens by over 80% when expanding from the collapsed configuration to the expanded configuration.
Clause 36. An expandable device for delivery to a target location in a body vessel, comprising: a frame comprising proximal and distal annular members, a first link member being coupled to the proximal and distal annular members, and a second link member being coupled to the proximal and distal annular members, wherein the frame is expandable from (1) a collapsed configuration, in which (i) the proximal and distal annular members are compressed into an oblong shape and oriented substantially parallel or oblique relative to a longitudinal axis of the frame, and (ii) the first and second link members extend substantially parallel relative to the longitudinal axis, to (2) an expanded configuration, in which (a) the proximal and distal annular members are substantially circular and biased toward a substantially perpendicular orientation relative to the longitudinal axis, and (b) the first and second link members foreshorten along the longitudinal axis to bias the proximal annular member toward the distal annular member; and a cover member coupled to the frame.
Clause 37. The device of Clause 36, wherein, in the collapsed configuration, the first and second link members have a first longitudinal extent, and in the expanded configuration, the first and second link members have a second longitudinal extent, the second longitudinal extent being less than the first longitudinal extent.
Clause 38. The device of any of Clauses 36-37, wherein, in the collapsed configuration, the proximal annular member extends along the longitudinal axis at a first longitudinal extent that is greater than a cross-sectional dimension of the proximal annular member, and wherein, in the collapsed configuration, the distal annular member is extends along the longitudinal axis at a second longitudinal extent that is greater than a cross-sectional dimension of the distal annular member.
Clause 39. The device of any of Clauses 36-38, wherein, in the collapsed configuration, the proximal and distal annular members longitudinally overlap each other.
Clause 40. The device of any of Clauses 36-39, wherein the first and second link members each comprise an arcuate body, biased to a substantially linear shape in the collapsed configuration and to a bowed shape in the expanded configuration.
Clause 41. The device of any of Clauses 36-40, wherein the first and second link members comprise springs.
Clause 42. The device of any of Clauses 36-41, wherein, in the expanded configuration, the first and second link members are substantially V-shaped.
Clause 43. The device of any of Clauses 36-42, wherein, in the expanded configuration, the first and second link members are substantially U-shaped.
Clause 44. The device of any of Clauses 36-43, wherein the first link member is coupled to first sides of the proximal and distal annular members and the second link member is coupled to second sides, opposing the first sides, of the proximal and distal annular members.
Clause 45. The device of any of Clauses 36-44, wherein the device foreshortens by over 20% when expanding from the collapsed configuration to the expanded configuration.
Clause 46. The device of any of Clauses 36-45, wherein the device foreshortens by over 30% when expanding from the collapsed configuration to the expanded configuration.
Clause 47. The device of any of Clauses 36-46, wherein the device foreshortens by over 40% when expanding from the collapsed configuration to the expanded configuration.
Clause 48. The device of any of Clauses 36-47, wherein the device foreshortens by over 50% when expanding from the collapsed configuration to the expanded configuration.
Clause 49. The device of any of Clauses 36-48, wherein the device foreshortens by over 60% when expanding from the collapsed configuration to the expanded configuration.
Clause 50. The device of any of Clauses 36-49, wherein the device foreshortens by over 70% when expanding from the collapsed configuration to the expanded configuration.
Clause 51. The device of any of Clauses 36-50, wherein the device foreshortens by over 80% when expanding from the collapsed configuration to the expanded configuration.
Clause 52. The device of any of Clauses 36-51, further comprising an intermediate annular member coupled to the first and second link members intermediate the proximal and distal annular members.
Clause 53. The device of any of Clauses 36-52, the first and second link members are coupled to the proximal annular member at first and second coupling points and to the distal annular member at third and fourth coupling points, wherein the first and second coupling points are spaced further apart from the third and fourth coupling points in the collapsed configuration and in the expanded configuration.
Clause 54. The device of any of Clauses 36-53, wherein the proximal and distal annular members have expanded diameters of between about 5 mm and about 15 mm.
Clause 55. The device of Clause 54, wherein the proximal and distal annular members have expanded diameters of between about 7 mm and about 13 mm.
Clause 56. The device of Clause 55, wherein the proximal and distal annular members have expanded diameters of between about 8 mm and about 12 mm.
Clause 57. The device of any of Clauses 36-56, wherein the device has a longitudinal length in the expanded configuration of between about 3 mm and about 12 mm.
Clause 58. The device of Clause 57, wherein the device has a longitudinal length in the expanded configuration of between about 4 mm and about 10 mm.
Clause 59. The device of Clause 58, wherein the device has a longitudinal length in the expanded configuration of between about 5 mm and about 7 mm.
Clause 60. A delivery system for delivering an occlusive device to a target vessel, the system comprising: a handle portion; a tubular shaft comprising a proximal end, coupled to the handle portion, and a distal end, comprising a lumen; a delivery component slidably disposed within the lumen and configured to advance an occlusive device within the lumen for delivery to the target vessel; an actuation component coupled to the handle portion and the delivery component for selectively advancing or retracting the delivery component relative to the shaft; and a release member coupled to the delivery component, the release member being movable between an engaged position in which the release member engages the occlusive device relative to the delivery component, and a disengaged position, in which the occlusive device is disengaged from the delivery component.
Clause 61. The system of Clause 60, wherein the shaft comprises a needle having a beveled tip.
Clause 62. The system of any of Clauses 60-61, wherein the lumen is between about 3 Fr and about 9 Fr.
Clause 63. The system of Clause 62, wherein the lumen is between about 4 Fr and about 8 Fr.
Clause 64. The system of Clause 63, wherein the lumen is between about 5 Fr and about 7 Fr.
Clause 65. The system of any of Clauses 60-64, wherein the shaft has a length of between about 8 cm to about 15 cm.
Clause 66. The system of Clause 65, wherein the shaft has a length of between about 10 cm to about 12 cm.
Clause 67. The system of any of Clauses 60-67, wherein the delivery component is configured to support an occlusive device along an outer surface thereof.
Clause 68. The system of any of Clauses 60-68, wherein the delivery component comprises a hollow tubular member.
Clause 69. The system of any of Clauses 60-69, wherein the delivery component comprises an atraumatic tip.
Clause 70. The system of Clause 69, wherein the delivery component comprises a rounded tip.
Clause 71. The system of Clause 69, wherein the tip comprises a substantially rounded conical shape.
Clause 72. The system of any of Clauses 69-71, wherein the tip is configured to support the device thereon.
Clause 73. The system of any of Clauses 60-72, wherein the release member comprises a wire extending through a lumen of the delivery component, the wire configured to engage at least one portion of a device supported on the delivery component.
Clause 74. The system of Clause 73, wherein the wire engages the device in two locations along the delivery component.
Clause 75. The system of Clause 74, wherein the delivery component comprises proximal and distal slots into which first and second portions of the device can be coupled with the wire.
Clause 76. A method of implanting an occlusive device, comprising: advancing a needle subcutaneously and into a target vessel, the needle having a lumen in which an occlusion device is disposed, the device comprising any of the devices recited in Clauses 1 to 59; and advancing the device out of the lumen to release the device into the target vessel.
Clause 77. The method of Clause 76, wherein the advancing comprises advancing the needle into a perforator artery.
Clause 78. The method of Clause 77, wherein the perforator vessel extends between a deep vein and a superficial vein in a limb of a patient.
Clause 79. The method of any of Clauses 77-78, wherein the perforator vessel comprises a thigh perforator, a knee perforator, a leg perforator, an ankle perforator, or a foot perforator.
Clause 80. The method of any of Clauses 77-79, wherein the perforator vessel comprises one of a Hunterian perforator, a Dodd perforator, a Boyd perforator, a Cockett perforator, a fibular perforator.
Clause 81. The method of any of Clauses 77-80, wherein the perforator vessel has a length of less than 10 cm.
Clause 82. The method of any of Clauses 77-81, wherein the perforator vessel has a length of less than 7 cm.
Clause 83. The method of any of Clauses 77-82, wherein the perforator vessel has a length of less than 5 cm.
Clause 84. The method of any of Clauses 76-83, wherein the advancing comprises advancing a delivery component from within the needle to expose the device within the vessel.
Clause 85. The method of Clause 84, further comprising, after advancing the delivery component from within the needle, proximally retracting an actuation component relative to the delivery component to release the device.
Clause 86. The method of Clause 85, wherein the proximally retracting comprises sequentially disengaging first and second portions of the device.
Clause 87. A method of implanting an occlusive device in a perforator vessel, the method comprising: introducing a needle through skin of a patient; advancing the needle into a perforator vessel, the perforator vessel extending between a superficial vein and a deep vein; distally advancing a delivery component from within the needle until a distal end of the delivery component extends into the deep vein; releasing a distal portion of the occlusive device into the deep vein; proximally withdrawing the needle from the perforator vessel such that the device is exposed within the vessel; and releasing a proximal portion of the device into the superficial vein such that the device blocks flow through the vessel.
Clause 88. The method of Clause 87, wherein the releasing the distal portion comprises proximally retracting an actuation component relative to the delivery component to disengage the distal portion from the delivery component.
Clause 89. The method of any of Clauses 87-88, wherein the releasing the proximal portion comprises proximally retracting an actuation component relative to the delivery component to disengage the proximal portion from the delivery component.
Clause 90. The method of any of Clauses 87-89, wherein upon releasing the proximal portion, the device foreshortens within the perforator vessel.
Clause 91. The method of any of Clauses 87-90, wherein the advancing comprises guiding the needle using an imaging component.
Clause 92. The method of Clause 91, wherein the imaging component comprises a handheld ultrasound device
Clause 93. The method of any of Clauses 87-92, wherein the introducing comprises introducing the needle through a from moral or jugular access point.
Further Considerations
The foregoing description is provided to enable a person skilled in the art to practice the various configurations described herein. While the subject technology has been particularly described with reference to the various figures and configurations, it should be understood that these are for illustration purposes only and should not be taken as limiting the scope of the subject technology.
There may be many other ways to implement the subject technology. Various functions and elements described herein may be partitioned differently from those shown without departing from the scope of the subject technology. Various modifications to these configurations will be readily apparent to those skilled in the art, and generic principles defined herein may be applied to other configurations. Thus, many changes and modifications may be made to the subject technology, by one having ordinary skill in the art, without departing from the scope of the subject technology.
It is understood that the specific order or hierarchy of steps in the processes disclosed is an illustration of exemplary approaches. Based upon design preferences, it is understood that the specific order or hierarchy of steps in the processes may be rearranged. Some of the steps may be performed simultaneously. The accompanying method claims present elements of the various steps in a sample order, and are not meant to be limited to the specific order or hierarchy presented.
As used herein, the phrase “at least one of” preceding a series of items, with the term “and” or “or” to separate any of the items, modifies the list as a whole, rather than each member of the list (i.e., each item). The phrase “at least one of” does not require selection of at least one of each item listed; rather, the phrase allows a meaning that includes at least one of any one of the items, and/or at least one of any combination of the items, and/or at least one of each of the items. By way of example, the phrases “at least one of A, B, and C” or “at least one of A, B, or C” each refer to only A, only B, or only C; any combination of A, B, and C; and/or at least one of each of A, B, and C.
Terms such as “top,” “bottom,” “front,” “rear” and the like as used in this disclosure should be understood as referring to an arbitrary frame of reference, rather than to the ordinary gravitational frame of reference. Thus, a top surface, a bottom surface, a front surface, and a rear surface may extend upwardly, downwardly, diagonally, or horizontally in a gravitational frame of reference.
Furthermore, to the extent that the term “include,” “have,” or the like is used in the description or the claims, such term is intended to be inclusive in a manner similar to the term “comprise” as “comprise” is interpreted when employed as a transitional word in a claim.
The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments.
A reference to an element in the singular is not intended to mean “one and only one” unless specifically stated, but rather “one or more.” Pronouns in the masculine (e.g., his) include the feminine and neuter gender (e.g., her and its) and vice versa. The term “some” refers to one or more. Underlined and/or italicized headings and subheadings are used for convenience only, do not limit the subject technology, and are not referred to in connection with the interpretation of the description of the subject technology. All structural and functional equivalents to the elements of the various configurations described throughout this disclosure that are known or later come to be known to those of ordinary skill in the art are expressly incorporated herein by reference and intended to be encompassed by the subject technology. Moreover, nothing disclosed herein is intended to be dedicated to the public regardless of whether such disclosure is explicitly recited in the above description.
While certain aspects and embodiments of the inventions have been described, these have been presented by way of example only, and are not intended to limit the scope of the inventions. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms without departing from the spirit thereof. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the inventions.
This application is a continuation of U.S. patent application Ser. No. 14/697,547, filed Apr. 27, 2015, which claims the priority benefit of U.S. Provisional Application No. 61/987,446, filed on May 1, 2014, the entirety of each of which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3805767 | Erb | Apr 1974 | A |
3868956 | Alfidi et al. | Mar 1975 | A |
3918431 | Sinnreich | Nov 1975 | A |
4013063 | Bucalo | Mar 1977 | A |
4245623 | Erb | Jan 1981 | A |
4553545 | Maass et al. | Nov 1985 | A |
4649922 | Wiktor | Mar 1987 | A |
4682592 | Thorsgard | Jul 1987 | A |
4705517 | DiPisa, Jr. | Nov 1987 | A |
4706671 | Weinrib | Nov 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4739762 | Palmaz | Apr 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4776337 | Palmaz | Oct 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4827946 | Kaali et al. | May 1989 | A |
4913141 | Hillstead | Apr 1990 | A |
4969890 | Sugita et al. | Nov 1990 | A |
5037427 | Harada et al. | Aug 1991 | A |
5065751 | Wolf | Nov 1991 | A |
5089005 | Harada | Feb 1992 | A |
5102417 | Palmaz | Apr 1992 | A |
5147370 | McNamara et al. | Sep 1992 | A |
5234437 | Sepetka | Aug 1993 | A |
5242451 | Harada et al. | Sep 1993 | A |
5242452 | Inoue | Sep 1993 | A |
5304198 | Samson | Apr 1994 | A |
5324306 | Makower et al. | Jun 1994 | A |
5334210 | Gianturco | Aug 1994 | A |
5342387 | Summers | Aug 1994 | A |
5372600 | Beyar et al. | Dec 1994 | A |
5417708 | Hall et al. | May 1995 | A |
5474089 | Waynant | Dec 1995 | A |
5476505 | Limon | Dec 1995 | A |
5499995 | Teirstein | Mar 1996 | A |
5536274 | Neuss | Jul 1996 | A |
5562641 | Flomenblit et al. | Oct 1996 | A |
5562698 | Parker | Oct 1996 | A |
5607445 | Summers | Mar 1997 | A |
5656036 | Palmaz | Aug 1997 | A |
5674287 | Slepian et al. | Oct 1997 | A |
5693083 | Baker et al. | Dec 1997 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5733329 | Wallace et al. | Mar 1998 | A |
5772668 | Summers et al. | Jun 1998 | A |
5782860 | Epstein et al. | Jul 1998 | A |
5797952 | Klein | Aug 1998 | A |
5797953 | Tekulve | Aug 1998 | A |
5830222 | Makower | Nov 1998 | A |
5842621 | Gschwind | Dec 1998 | A |
5868782 | Frantzen | Feb 1999 | A |
5902266 | Leone et al. | May 1999 | A |
5922009 | Epstein et al. | Jul 1999 | A |
5925063 | Khosravi | Jul 1999 | A |
5925074 | Gingras et al. | Jul 1999 | A |
5928260 | Chin et al. | Jul 1999 | A |
5944738 | Amplatz et al. | Aug 1999 | A |
5954766 | Zadno-Azizi et al. | Sep 1999 | A |
5957929 | Brenneman | Sep 1999 | A |
5979446 | Loy | Nov 1999 | A |
6010517 | Baccaro | Jan 2000 | A |
6019779 | Thorud et al. | Feb 2000 | A |
6024765 | Wallace et al. | Feb 2000 | A |
6056770 | Epstein et al. | May 2000 | A |
6059825 | Hobbs et al. | May 2000 | A |
6083257 | Taylor et al. | Jul 2000 | A |
6117157 | Tekulve | Sep 2000 | A |
6123715 | Amplatz | Sep 2000 | A |
6168622 | Mazzocchi | Jan 2001 | B1 |
6190353 | Makower et al. | Feb 2001 | B1 |
6210338 | Afremov et al. | Apr 2001 | B1 |
6214042 | Jacobsen et al. | Apr 2001 | B1 |
6241678 | Afremov et al. | Jun 2001 | B1 |
6241758 | Cox | Jun 2001 | B1 |
6245090 | Gilson et al. | Jun 2001 | B1 |
6248122 | Klumb et al. | Jun 2001 | B1 |
6258119 | Hussein et al. | Jul 2001 | B1 |
6283983 | Makower et al. | Sep 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6346118 | Baker et al. | Feb 2002 | B1 |
6361558 | Hieshima et al. | Mar 2002 | B1 |
6368339 | Amplatz | Apr 2002 | B1 |
6371953 | Beyar et al. | Apr 2002 | B1 |
6371979 | Beyar et al. | Apr 2002 | B1 |
6402760 | Fedida | Jun 2002 | B1 |
6402772 | Amplatz et al. | Jun 2002 | B1 |
6432116 | Callister et al. | Aug 2002 | B1 |
6432127 | Kim et al. | Aug 2002 | B1 |
6447531 | Amplatz | Sep 2002 | B1 |
6451025 | Jervis | Sep 2002 | B1 |
6454780 | Wallace | Sep 2002 | B1 |
6464712 | Epstein et al. | Oct 2002 | B1 |
6468301 | Amplatz et al. | Oct 2002 | B1 |
6485524 | Strecker | Nov 2002 | B2 |
6506204 | Mazzocchi | Jan 2003 | B2 |
6514285 | Pinchasik | Feb 2003 | B1 |
6533805 | Jervis | Mar 2003 | B1 |
6550480 | Feldman et al. | Apr 2003 | B2 |
6554849 | Jones et al. | Apr 2003 | B1 |
6562064 | deBeer | May 2003 | B1 |
6572643 | Gharibadeh | Jun 2003 | B1 |
6579303 | Amplatz | Jun 2003 | B2 |
6585760 | Fogarty | Jul 2003 | B1 |
6599308 | Amplatz | Jul 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6613074 | Mitelberg | Sep 2003 | B1 |
6616675 | Evard et al. | Sep 2003 | B1 |
6623518 | Thompson et al. | Sep 2003 | B2 |
6629981 | Bui et al. | Oct 2003 | B2 |
6638243 | Kupiecki | Oct 2003 | B2 |
6638257 | Amplatz | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6645237 | Klumb et al. | Nov 2003 | B2 |
6656207 | Epstein et al. | Dec 2003 | B2 |
6660020 | Wallace et al. | Dec 2003 | B2 |
6660032 | Klumb et al. | Dec 2003 | B2 |
6663666 | Quiachon et al. | Dec 2003 | B1 |
6682546 | Amplatz | Jan 2004 | B2 |
6689148 | Sawhney et al. | Feb 2004 | B2 |
6702846 | Mikus et al. | Mar 2004 | B2 |
6719781 | Kim | Apr 2004 | B1 |
6790218 | Jayaraman | Sep 2004 | B2 |
6849081 | Sepetka et al. | Feb 2005 | B2 |
6872211 | White et al. | Mar 2005 | B2 |
6890341 | Dieck et al. | May 2005 | B2 |
6899730 | Rivelli, Jr. | May 2005 | B1 |
6936058 | Forde et al. | Aug 2005 | B2 |
6974473 | Barclay et al. | Dec 2005 | B2 |
6984244 | Perez et al. | Jan 2006 | B2 |
7001409 | Amplatz | Feb 2006 | B2 |
7011643 | Villafana et al. | Mar 2006 | B2 |
7011671 | Welch | Mar 2006 | B2 |
7144408 | Keegan et al. | Dec 2006 | B2 |
7152605 | Khairkhahan et al. | Dec 2006 | B2 |
7220270 | Sawhney et al. | May 2007 | B2 |
7270668 | Andreas et al. | Sep 2007 | B2 |
7276077 | Zadno-Azizi et al. | Oct 2007 | B2 |
7294146 | Chew et al. | Nov 2007 | B2 |
7303571 | Makower et al. | Dec 2007 | B2 |
7387641 | Schmitt | Jun 2008 | B2 |
7396362 | Jervis | Jul 2008 | B2 |
7398780 | Callister et al. | Jul 2008 | B2 |
7458986 | Schmitt | Dec 2008 | B2 |
7476232 | Deal | Jan 2009 | B2 |
7582100 | Johnson et al. | Sep 2009 | B2 |
7597704 | Frazier et al. | Oct 2009 | B2 |
7604649 | McGuckin, Jr. et al. | Oct 2009 | B2 |
7632291 | Stephens et al. | Dec 2009 | B2 |
7647930 | Ginn | Jan 2010 | B2 |
7651521 | Ton et al. | Jan 2010 | B2 |
7666204 | Thornton et al. | Feb 2010 | B2 |
7682673 | Houston et al. | Mar 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7699056 | Tran et al. | Apr 2010 | B2 |
7740616 | Smith et al. | Jun 2010 | B2 |
7771463 | Ton et al. | Aug 2010 | B2 |
7785343 | Johnson et al. | Aug 2010 | B2 |
7785631 | Roser et al. | Aug 2010 | B2 |
7789860 | Brady et al. | Sep 2010 | B2 |
7789892 | Johnson et al. | Sep 2010 | B2 |
7803177 | Hartley et al. | Sep 2010 | B2 |
7854747 | Johnson et al. | Dec 2010 | B2 |
7955343 | Makower et al. | Jun 2011 | B2 |
7967837 | Vale | Jun 2011 | B2 |
7985250 | Kaufmann et al. | Jul 2011 | B2 |
7992565 | McGuckin, Jr. et al. | Aug 2011 | B2 |
8016870 | Chew et al. | Sep 2011 | B2 |
8016880 | Cook et al. | Sep 2011 | B2 |
8043357 | Hartley | Oct 2011 | B2 |
8100958 | Fischer et al. | Jan 2012 | B2 |
8110267 | Houston et al. | Feb 2012 | B2 |
8114114 | Belson | Feb 2012 | B2 |
8118852 | Melsheimer | Feb 2012 | B2 |
8142456 | Rosqueta et al. | Mar 2012 | B2 |
8162970 | Gilson et al. | Apr 2012 | B2 |
8226679 | Johnson et al. | Jul 2012 | B2 |
8226704 | Caro et al. | Jul 2012 | B2 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
8308754 | Belson | Nov 2012 | B2 |
8323305 | Epstein et al. | Dec 2012 | B2 |
8323350 | Nissl | Dec 2012 | B2 |
8328840 | Gailloud et al. | Dec 2012 | B2 |
8333783 | Braun et al. | Dec 2012 | B2 |
8333796 | Tompkins et al. | Dec 2012 | B2 |
8343167 | Henson | Jan 2013 | B2 |
8348994 | Leopold et al. | Jan 2013 | B2 |
8382771 | Gellman et al. | Feb 2013 | B2 |
8382821 | Richter | Feb 2013 | B2 |
8398700 | Leopold et al. | Mar 2013 | B2 |
8425549 | Lenker et al. | Apr 2013 | B2 |
8430904 | Belson | Apr 2013 | B2 |
8663301 | Riina et al. | Mar 2014 | B2 |
20010000798 | Denardo | May 2001 | A1 |
20010007946 | Lenker et al. | Jul 2001 | A1 |
20010031981 | Evans et al. | Oct 2001 | A1 |
20010037146 | Lau et al. | Nov 2001 | A1 |
20010044648 | Wolinsky et al. | Nov 2001 | A1 |
20010046518 | Sawhney | Nov 2001 | A1 |
20020007206 | Bui et al. | Jan 2002 | A1 |
20020091439 | Baker et al. | Jul 2002 | A1 |
20020099437 | Anson et al. | Jul 2002 | A1 |
20020107565 | Greenhalgh | Aug 2002 | A1 |
20020123765 | Sepetka et al. | Sep 2002 | A1 |
20020128707 | Kavteladze et al. | Sep 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020177855 | Greene et al. | Nov 2002 | A1 |
20020198588 | Armstrong et al. | Dec 2002 | A1 |
20030114922 | Iwasaka et al. | Jun 2003 | A1 |
20030125798 | Martin | Jul 2003 | A1 |
20030130684 | Brady et al. | Jul 2003 | A1 |
20030153972 | Helmus | Aug 2003 | A1 |
20030163146 | Epstein et al. | Aug 2003 | A1 |
20030171801 | Bates | Sep 2003 | A1 |
20030187474 | Keegan et al. | Oct 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030216679 | Wolf et al. | Nov 2003 | A1 |
20030229366 | Reggie et al. | Dec 2003 | A1 |
20040010282 | Kusleika | Jan 2004 | A1 |
20040029994 | Cheng et al. | Feb 2004 | A1 |
20040044360 | Lowe | Mar 2004 | A1 |
20040055606 | Hendricksen et al. | Mar 2004 | A1 |
20040073252 | Goldberg et al. | Apr 2004 | A1 |
20040147869 | Wolf et al. | Jul 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040158308 | Hogendijk et al. | Aug 2004 | A1 |
20040193141 | Leopold et al. | Sep 2004 | A1 |
20040220663 | Rivelli | Nov 2004 | A1 |
20040225286 | Elliott | Nov 2004 | A1 |
20040243219 | Fischer et al. | Dec 2004 | A1 |
20040249342 | Khosravi et al. | Dec 2004 | A1 |
20040254517 | Quiroz-Mercado et al. | Dec 2004 | A1 |
20040260384 | Allen | Dec 2004 | A1 |
20050027305 | Shiu et al. | Feb 2005 | A1 |
20050033409 | Burke et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050055079 | Duran | Mar 2005 | A1 |
20050055082 | Ben Muvhar et al. | Mar 2005 | A1 |
20050113902 | Geiser et al. | May 2005 | A1 |
20050137681 | Shoemaker et al. | Jun 2005 | A1 |
20050165442 | Thinnes et al. | Jul 2005 | A1 |
20050192616 | Callister et al. | Sep 2005 | A1 |
20050209675 | Ton et al. | Sep 2005 | A1 |
20050288684 | Aronson et al. | Dec 2005 | A1 |
20060009798 | Callister et al. | Jan 2006 | A1 |
20060052822 | Mirizzi | Mar 2006 | A1 |
20060111771 | Ton et al. | May 2006 | A1 |
20060119714 | Tamura et al. | Jun 2006 | A1 |
20060149359 | Richter et al. | Jul 2006 | A1 |
20060162731 | Wondka et al. | Jul 2006 | A1 |
20060178727 | Richter | Aug 2006 | A1 |
20060184089 | Makower et al. | Aug 2006 | A1 |
20060200191 | Zadno-Azizi | Sep 2006 | A1 |
20060241675 | Johnson et al. | Oct 2006 | A1 |
20060241690 | Amplatz et al. | Oct 2006 | A1 |
20070038178 | Kusleika | Feb 2007 | A1 |
20070043419 | Nikolchev et al. | Feb 2007 | A1 |
20070060946 | Keegan et al. | Mar 2007 | A1 |
20070088388 | Opolski et al. | Apr 2007 | A1 |
20070112381 | Figulla et al. | May 2007 | A1 |
20070118209 | Strecker | May 2007 | A1 |
20070129753 | Quinn et al. | Jun 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070150045 | Ferrera | Jun 2007 | A1 |
20070156224 | Cioanta et al. | Jul 2007 | A1 |
20070163601 | Pollock et al. | Jul 2007 | A1 |
20070168018 | Amplatz et al. | Jul 2007 | A1 |
20070168019 | Amplatz et al. | Jul 2007 | A1 |
20070203503 | Salahieh et al. | Aug 2007 | A1 |
20070221230 | Thompson et al. | Sep 2007 | A1 |
20070233186 | Meng | Oct 2007 | A1 |
20070239191 | Ramzipoor | Oct 2007 | A1 |
20070247680 | Nakane et al. | Oct 2007 | A1 |
20070265656 | Amplatz et al. | Nov 2007 | A1 |
20070265658 | Nelson et al. | Nov 2007 | A1 |
20080017201 | Sawhney | Jan 2008 | A1 |
20080045996 | Makower et al. | Feb 2008 | A1 |
20080046092 | Davis et al. | Feb 2008 | A1 |
20080086214 | Hardin et al. | Apr 2008 | A1 |
20080103522 | Steingisser et al. | May 2008 | A1 |
20080132906 | Rasmussen | Jun 2008 | A1 |
20080178890 | Townsend et al. | Jul 2008 | A1 |
20080200945 | Amplatz et al. | Aug 2008 | A1 |
20080215087 | Pavcnik et al. | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080221666 | Licata et al. | Sep 2008 | A1 |
20080269719 | Balgobin et al. | Oct 2008 | A1 |
20080302368 | McGuckin, Jr. et al. | Dec 2008 | A1 |
20090005847 | Adams | Jan 2009 | A1 |
20090018562 | Amplatz et al. | Jan 2009 | A1 |
20090018636 | Gailloud et al. | Jan 2009 | A1 |
20090025820 | Adams | Jan 2009 | A1 |
20090030497 | Metcalf et al. | Jan 2009 | A1 |
20090043330 | To | Feb 2009 | A1 |
20090062841 | Amplatz | Mar 2009 | A1 |
20090078270 | Meier et al. | Mar 2009 | A1 |
20090082803 | Adams et al. | Mar 2009 | A1 |
20090099647 | Glimsdale et al. | Apr 2009 | A1 |
20090112251 | Qian et al. | Apr 2009 | A1 |
20090131959 | Rolland | May 2009 | A1 |
20090132020 | Watson | May 2009 | A1 |
20090138078 | Paul, Jr. et al. | May 2009 | A1 |
20090157053 | Davis et al. | Jun 2009 | A1 |
20090171386 | Amplatz et al. | Jul 2009 | A1 |
20090178682 | Tal et al. | Jul 2009 | A1 |
20090187214 | Amplatz et al. | Jul 2009 | A1 |
20090209855 | Drilling et al. | Aug 2009 | A1 |
20090210047 | Amplatz et al. | Aug 2009 | A1 |
20090210048 | Amplatz et al. | Aug 2009 | A1 |
20090216185 | Gregorich et al. | Aug 2009 | A1 |
20090240326 | Wilson et al. | Sep 2009 | A1 |
20090276029 | Caro et al. | Nov 2009 | A1 |
20090276039 | Meretei | Nov 2009 | A1 |
20090277455 | Lee-Sepsick et al. | Nov 2009 | A1 |
20090281610 | Parker | Nov 2009 | A1 |
20100006105 | Carter et al. | Jan 2010 | A1 |
20100030321 | Mach | Feb 2010 | A1 |
20100049307 | Ren | Feb 2010 | A1 |
20100057194 | Ryan | Mar 2010 | A1 |
20100063578 | Ren et al. | Mar 2010 | A1 |
20100063582 | Rudakov | Mar 2010 | A1 |
20100089406 | Kachiguina | Apr 2010 | A1 |
20100094395 | Kellett | Apr 2010 | A1 |
20100106235 | Kariniemi et al. | Apr 2010 | A1 |
20100114307 | Agnew et al. | May 2010 | A1 |
20100121370 | Kariniemi | May 2010 | A1 |
20100174269 | Tompkins et al. | Jul 2010 | A1 |
20100198328 | Hartley et al. | Aug 2010 | A1 |
20100223046 | Bucchieri et al. | Sep 2010 | A1 |
20100223048 | Lauder | Sep 2010 | A1 |
20100249691 | Van Der Mooren et al. | Sep 2010 | A1 |
20100256661 | Brandeis | Oct 2010 | A1 |
20100268201 | Tieu et al. | Oct 2010 | A1 |
20100268260 | Riina et al. | Oct 2010 | A1 |
20100294282 | Chu et al. | Nov 2010 | A1 |
20100312268 | Belson | Dec 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20100324585 | Miles et al. | Dec 2010 | A1 |
20100324586 | Miles et al. | Dec 2010 | A1 |
20100324587 | Miles et al. | Dec 2010 | A1 |
20100324588 | Miles et al. | Dec 2010 | A1 |
20110029067 | McGuckin, Jr. et al. | Feb 2011 | A1 |
20110040371 | Hanssen et al. | Feb 2011 | A1 |
20110092997 | Kang | Apr 2011 | A1 |
20110124958 | Nelson | May 2011 | A1 |
20110125132 | Krolik et al. | May 2011 | A1 |
20110202087 | Vale | Aug 2011 | A1 |
20110202129 | Fofsell | Aug 2011 | A1 |
20110218479 | Rottenberg et al. | Sep 2011 | A1 |
20110264132 | Strauss et al. | Oct 2011 | A1 |
20110264195 | Griswold | Oct 2011 | A1 |
20110282343 | Kunis | Nov 2011 | A1 |
20110301630 | Hendriksen et al. | Dec 2011 | A1 |
20110313506 | Ray et al. | Dec 2011 | A1 |
20110319906 | Rudakov et al. | Dec 2011 | A1 |
20120010556 | Faul et al. | Jan 2012 | A1 |
20120022572 | Braun et al. | Jan 2012 | A1 |
20120059458 | Buchbinder | Mar 2012 | A1 |
20120071918 | Amin | Mar 2012 | A1 |
20120083822 | Anukhin et al. | Apr 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120095489 | Rudakov et al. | Apr 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120116350 | Strauss et al. | May 2012 | A1 |
20120123511 | Brown | May 2012 | A1 |
20120123514 | Kunis | May 2012 | A1 |
20120143301 | Maslanka et al. | Jun 2012 | A1 |
20120172911 | Welch | Jul 2012 | A1 |
20120192872 | Rudakov et al. | Aug 2012 | A1 |
20120209310 | Chen et al. | Aug 2012 | A1 |
20120239077 | Zaver et al. | Sep 2012 | A1 |
20120245614 | Drasler | Sep 2012 | A1 |
20120245620 | Gilson et al. | Sep 2012 | A1 |
20120245668 | Kariniemi et al. | Sep 2012 | A1 |
20120259354 | Kellett | Oct 2012 | A1 |
20120277842 | Kunis | Nov 2012 | A1 |
20120289988 | Riina et al. | Nov 2012 | A1 |
20120289994 | Larson et al. | Nov 2012 | A1 |
20120296408 | Jones et al. | Nov 2012 | A1 |
20120316584 | Miles et al. | Dec 2012 | A1 |
20120330347 | Becking et al. | Dec 2012 | A1 |
20120330348 | Strauss et al. | Dec 2012 | A1 |
20130041404 | Amin | Feb 2013 | A1 |
20130053879 | Gailloud et al. | Feb 2013 | A1 |
20130102996 | Strauss | Apr 2013 | A1 |
20130103074 | Riina et al. | Apr 2013 | A1 |
20130109987 | Kunis et al. | May 2013 | A1 |
20130116774 | Strauss et al. | May 2013 | A1 |
20130123899 | Leopold et al. | May 2013 | A1 |
20130178889 | Miles et al. | Jul 2013 | A1 |
20130204282 | Nelson | Aug 2013 | A1 |
20130204311 | Kunis | Aug 2013 | A1 |
20130289714 | Strauss et al. | Oct 2013 | A1 |
20140128780 | Kennedy et al. | May 2014 | A1 |
20140207180 | Ferrera | Jul 2014 | A1 |
20140215792 | Leopold et al. | Aug 2014 | A1 |
20140222059 | Leopold et al. | Aug 2014 | A1 |
20140257369 | Leopold et al. | Sep 2014 | A1 |
20140277085 | Mirigian et al. | Sep 2014 | A1 |
20140371716 | Rudakov | Dec 2014 | A1 |
20140371777 | Rudakov et al. | Dec 2014 | A1 |
20140371778 | Rudakov et al. | Dec 2014 | A1 |
20150057700 | Chen et al. | Feb 2015 | A1 |
20150157329 | Rudakov et al. | Jun 2015 | A1 |
20150157333 | Leopold et al. | Jun 2015 | A1 |
20150223821 | Rudakov et al. | Aug 2015 | A1 |
20150290437 | Rudakov et al. | Oct 2015 | A1 |
20150342611 | Leopold et al. | Dec 2015 | A1 |
Number | Date | Country |
---|---|---|
2527227 | Dec 2002 | CN |
1166721 | Jan 2002 | EP |
1188413 | Mar 2002 | EP |
1317908 | Jun 2003 | EP |
1600110 | Nov 2005 | EP |
1707233 | Oct 2006 | EP |
1752112 | Feb 2007 | EP |
1813196 | Aug 2007 | EP |
1820436 | Aug 2007 | EP |
1852073 | Nov 2007 | EP |
2248471 | Nov 2010 | EP |
2366362 | Sep 2011 | EP |
2366363 | Sep 2011 | EP |
2366364 | Sep 2011 | EP |
2404580 | Jan 2012 | EP |
2583636 | Apr 2013 | EP |
2404860 | Feb 2005 | GB |
2494820 | Mar 2013 | GB |
H 07-000405 | Jan 1995 | JP |
H 07-185011 | Jul 1995 | JP |
2006-181015 | Jul 2006 | JP |
2010-532180 | Oct 2010 | JP |
2012-525859 | Oct 2012 | JP |
WO 8300997 | Mar 1983 | WO |
WO 9214408 | Sep 1992 | WO |
WO 94000179 | Jan 1994 | WO |
WO 9524158 | Sep 1995 | WO |
WO 9525480 | Sep 1995 | WO |
WO 9532018 | Nov 1995 | WO |
WO 9618361 | Jun 1996 | WO |
WO 9713463 | Apr 1997 | WO |
WO 9713471 | Apr 1997 | WO |
WO 9727893 | Aug 1997 | WO |
WO 9727897 | Aug 1997 | WO |
WO 9727898 | Aug 1997 | WO |
WO 9731672 | Sep 1997 | WO |
WO 9808456 | Mar 1998 | WO |
WO 9831308 | Jul 1998 | WO |
WO 9834546 | Aug 1998 | WO |
WO 9846115 | Oct 1998 | WO |
WO 9846119 | Oct 1998 | WO |
WO 9912484 | Mar 1999 | WO |
WO 9923976 | May 1999 | WO |
WO 9925273 | May 1999 | WO |
WO 9944542 | Sep 1999 | WO |
WO 9948545 | Sep 1999 | WO |
WO 9949793 | Oct 1999 | WO |
WO 9949910 | Oct 1999 | WO |
WO 9962430 | Dec 1999 | WO |
WO 0009195 | Feb 2000 | WO |
WO 0016847 | Mar 2000 | WO |
WO 0027303 | May 2000 | WO |
WO 0067671 | Nov 2000 | WO |
WO 01032254 | May 2001 | WO |
WO 0164112 | Sep 2001 | WO |
WO 01080776 | Nov 2001 | WO |
WO 01080777 | Nov 2001 | WO |
WO 0189413 | Nov 2001 | WO |
WO 0203889 | Jan 2002 | WO |
WO 03001970 | Jan 2003 | WO |
WO 03073961 | Sep 2003 | WO |
WO 03073962 | Sep 2003 | WO |
WO 03101518 | Dec 2003 | WO |
WO 2004006804 | Jan 2004 | WO |
WO 2004073557 | Sep 2004 | WO |
WO 2005020786 | Mar 2005 | WO |
WO 2005092241 | Oct 2005 | WO |
WO 2005117755 | Dec 2005 | WO |
WO 2006017470 | Feb 2006 | WO |
WO 2006028943 | Mar 2006 | WO |
WO 2006031602 | Mar 2006 | WO |
WO 2006034153 | Mar 2006 | WO |
WO 2006074163 | Jul 2006 | WO |
WO 2006096342 | Sep 2006 | WO |
WO 2006111801 | Oct 2006 | WO |
WO 2006134354 | Dec 2006 | WO |
WO 2007061927 | May 2007 | WO |
WO 2007070544 | Jun 2007 | WO |
WO 2007085373 | Aug 2007 | WO |
WO 2007127351 | Nov 2007 | WO |
WO 2007149844 | Dec 2007 | WO |
WO 2008010197 | Jan 2008 | WO |
WO 2008100790 | Aug 2008 | WO |
WO 2008112501 | Sep 2008 | WO |
WO 2008153653 | Dec 2008 | WO |
WO 2009064618 | May 2009 | WO |
WO 2009077845 | Jun 2009 | WO |
WO 2009088905 | Jul 2009 | WO |
WO 2009124288 | Oct 2009 | WO |
WO 2009126747 | Oct 2009 | WO |
WO 2010009019 | Jan 2010 | WO |
WO 2010047644 | Apr 2010 | WO |
WO 2010075565 | Jul 2010 | WO |
WO 2010085344 | Jul 2010 | WO |
WO 2010096717 | Aug 2010 | WO |
WO 2010130617 | Nov 2010 | WO |
WO 2010135352 | Nov 2010 | WO |
WO 2010146581 | Dec 2010 | WO |
WO 2010148246 | Dec 2010 | WO |
WO 2011011581 | Jan 2011 | WO |
WO 2011153304 | Dec 2011 | WO |
WO 2011163157 | Dec 2011 | WO |
WO 2012002944 | Jan 2012 | WO |
WO 2012040380 | Mar 2012 | WO |
WO 2012067724 | May 2012 | WO |
WO 2012109367 | Aug 2012 | WO |
WO 2012111137 | Aug 2012 | WO |
WO 2012120490 | Sep 2012 | WO |
WO 2012131672 | Oct 2012 | WO |
WO 2012134761 | Oct 2012 | WO |
WO 2012135859 | Oct 2012 | WO |
WO 2012166804 | Dec 2012 | WO |
WO 2013055703 | Apr 2013 | WO |
WO 2013059511 | Apr 2013 | WO |
WO 2013067299 | May 2013 | WO |
Entry |
---|
U.S. Appl. No. 11/825,956, filed Jul. 9, 2007, now U.S. Pat. No. 8,328,840. |
U.S. Appl. No. 12/826,593, filed Jun. 29, 2010, now U.S. Pub. 2011/0319906. |
U.S. Appl. No. 12/906,993, filed Oct. 18, 2010, now U.S. Pub. 2012/0095489. |
U.S. Appl. No. 13/367,338, filed Feb. 6, 2012, now U.S. Pub. 2012/0192872. |
U.S. Appl. No. 13/670,345, filed Nov. 6, 2012, now U.S. Pub. 2013/0053879. |
U.S. Appl. No. 13/828,974, filed Mar. 14, 2013, now U.S. Pub. 2014/0222059. |
U.S. Appl. No. 14/044,794, filed Oct. 2, 2013, now U.S. Pub. 2014/0215792. |
U.S. Appl. No. 14/101,171, filed Dec. 9, 2013, now U.S. Pub. 2014/0371716. |
U.S. Appl. No. 14/281,797, filed May 19, 2014, now U.S. Pub. 2014/0257369. |
U.S. Appl. No. 14/304,868, filed Jun. 13, 2014, now U.S. Pub. 2014/0371777. |
U.S. Appl. No. 14/304,869, filed Jun. 13, 2014, now U.S. Pub. 2014/0371778. |
U.S. Appl. No. 14/622,729, filed Feb. 13, 2015, now U.S. Pub. 2015/0157329. |
U.S. Appl. No. 14/628,096, filed Feb. 20, 2015, now U.S. Pub. 2015/0157333. |
U.S. Appl. No. 14/688,915, filed Apr. 16, 2015, now U.S. Pub. 2015/0223821. |
U.S. Appl. No. 14/697,547, filed Apr. 27, 2015, now U.S. Pub. 2015/0313602. |
U.S. Appl. No. 14/749,565, filed Jun. 24, 2015, now U.S. Pub. 2015/0290437. |
Aydogan, Transcatheter Embolization Treatment of Coronary Arteriovenous Fistulas, Asian Cardiovascular & Thoracic Annals, 2003, pp. 63-67, vol. 11, No. 1. |
Berguer et al., Cure by Combination of Operation and Detachable Intravascular Balloon, Ann. Surg. Jul. 1982, pp. 65-68, vol. 196, No. 1. |
Cheng et al., Minimally Invasive Keyhole Approach for Removal of a Migratory Balloon Complicated by Endovascular Embolization of a Carotid-Cavernous Fistula, Minim. Invasive Neurosurgl, 2006, pp. 305-308, vol. 49. |
Desouza et al., Embolization with detachable Balloons—Applications outside the head, Clinical Radiology, Apr. 21, 1992, pp. 170-175, vol. 46. |
Ferro et al, Percutaneous Transcatheter Embolization of a Large Pulmonary Arteriovenous Fistula with an Amplatzer Vascular Plug, Cardovacs Intervent Radiol, 2007, pp. 328-331, vol. 30. |
Hawkins et al., The Permeability of Detachable Latex Rubber Balloons—An In Vitro Study, Investigative Radiology, Dec. 1987, pp. 969-972, vol. 22. |
Hirai et al., Emergency Balloon Embolization for Carotid Artery Rupture Secondary to Postoperative Infection, Cardiovasc Intervent Radiol, 1996, pp. 50-52, vol. 19. |
Kadir et al., Therapeutic Embolization of the Kidney with Detachable Silicone Balloons, The Journal of Urology, Jan. 1983, pp. 11-13, vol. 129. |
Kallmes et al., The Use of Hydrocoil for Parent Artery Occlusion, AJNR Am J Neuroradiol, Sep. 2004, pp. 1409-1410, vol. 25. |
Kaufman, et al., Detachable Balloon-modified Reducing Stent to Treat Hepatic Insufficiency after Transjugular Intrahepatic Portosystemic Shunt Creation, J Vasc Interv Radiol., May 2003, pp. 635-638, vol. 14, No. 5. |
Luo, Chao-Bao et al., Endovascular Treatment of the Carotid Artery Rupture with Massive Hemorrhage, J. Chin Med Assoc., Mar. 2003. |
Makita, et al., Guide-Wire-directed Detachable Balloon: Clinical Application in Treatment of Varicoceles, Radiology, 1992, pp. 575-577, vol. 183. |
Marshall et al., Treatment of Traumatic Renal Arteriovenous Fistulas by Detachable Silicone Balloon Embolization, The Journal of Urology, Aug. 1979, pp. 237-239, vol. 122. |
Perala et al., Comparison of Early Deflation Rate of Detachable Latex and Silicone Balloons and Observations on Persistent Varicocele, J. Vasc. Interv. Radiol. Sep.-Oct. 1998, pp. 761-765, vol. 9, No. 5. |
Pollak et al., Clinical Results of Transvenous Systemic Embolotherapy with a Neuroradiologic Detachable Balloon, Radiology, May 1994, pp. 477-482, vol. 191, No. 2. |
Reidy et at., Transcatherer occlusion of coronary to bronchial anastomosis by detachable balloon combined with coronary angioplasty at same procedure, Brit Heart J. 1983, pp. 284-287, vol. 49. |
Reidy et al., Transcatheter occlusion of a Blalock-Taussig shunt with a detachable balloon in a child, Bri Heart Journal, 1983, pp. 101-103, vol. 50. |
Ross et al., The Vascular Plug: A New Device for Parent Artery Occlusion, AJNR Am J Neuroradiol, Feb. 2007, pp. 385-386, vol. 28. |
Serbinenko, F.A., Balloon Catheterization and Occlusion of Major Cerebral Vessels, J. Neurosurg. Aug. 1974, pp. 125-145, vol. 41. |
Tasar, et al., Intrahepatic arterioportal fistula and its treatment with detachable balloon and transcatheter embolization with coils and microspheres, Journal of Clinical Imaging, 2005, pp. 325-330, vol. 29. |
Wehman, et al., Giant Cerebral Aneurysms: Endovascular Challenges, Neurosurgery, Nov. 2006, pp. S125-S138, vol. 59, No. 5. |
White, et al., Occlusion of Varicoceles with Detachable Balloons, Radiology, May 1981, pp. 327-334, vol. 139. |
Serbinenko, F.A., Occlusion by Balooning of Sacular Aneurysms of the Cerebral Arteries, Vopr, Neirokhir, Jul.-Aug. 1974, pp. 8-15, vol. 4. |
Serebinko, F.A., Balloon Occlusion of Cavernous Portion of the Carotid Artery as a Method of Treating Carotid Cavity Anastomoses, Vopr. Neirokhir, Nov.-Dec. 1971, pp. 3-9, vol. 6. |
Number | Date | Country | |
---|---|---|---|
20190343530 A1 | Nov 2019 | US |
Number | Date | Country | |
---|---|---|---|
61987446 | May 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14697547 | Apr 2015 | US |
Child | 16518933 | US |